Share Email Print

Proceedings Paper

Laser therapy and macular degeneration
Author(s): Ugo Menchini; Gianni Virgili; Fabrizio Giansanti; Giovanni Giacomelli; Stefania Cappelli
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Among macular diseases, choroidal neovascularization (CNV) is one of the most common causes of visual loss, especially in the form associated with age-related macular degeneration and pathologic myopia. Research on these diseases has recently evaluated new treatment modalities that use laser light differently; among these, photodynamic therapy (PDT) has been introduced in the clinical practice, allowing us to expand the possibility of reducing visual loss in patients affected by CNV. With PDT, a photosensitizer (verteporfin, VisudyneTM) is injected intravenously, and it selectively binds to new vessels; low-power laser light exposure then activates the drug, leading to oxidative damage of the endothelium and new vessels thrombosis. Yet, other therapies, such as transpupillary termotherapy, or the use of photocoagulation to cause feeder-vessel occlusion, could proof effective, but they need further investigation.

Paper Details

Date Published: 23 October 2001
PDF: 5 pages
Proc. SPIE 4606, Laser Florence 2000: A Window on the Laser Medicine World, (23 October 2001); doi: 10.1117/12.446718
Show Author Affiliations
Ugo Menchini, Eye Clinic II/Univ. of Florence (Italy)
Gianni Virgili, Eye Clinic II/Univ. of Florence (Italy)
Fabrizio Giansanti, Eye Clinic II/Univ. of Florence (Italy)
Giovanni Giacomelli, Eye Clinic II/Univ. of Florence (Italy)
Stefania Cappelli, Eye Clinic II/Univ. of Florence (Italy)

Published in SPIE Proceedings Vol. 4606:
Laser Florence 2000: A Window on the Laser Medicine World
Leonardo Longo; Alfons G. Hofstetter; Mihail-Lucian Pascu; Wilhelm R.A. Waidelich, Editor(s)

© SPIE. Terms of Use
Back to Top